10A NCAC 41A .0101 is amended with changes as published in 30:23 NCR 2435-2437 as follows:

3	10A NCAC 41A	.0101 REPORTABLE DISEASES AND CONDITIONS
4	(a) The followin	ng named diseases and conditions are declared to be dangerous to the public health and are hereby
5	made reportable	within the time period specified after the disease or condition is reasonably suspected to exist:
6	(1)	acquired immune deficiency syndrome (AIDS) - 24 hours;
7	(2)	anthrax - immediately;
8	(3)	botulism - immediately;
9	(4)	brucellosis - 7 days;
10	(5)	campylobacter infection - 24 hours;
11	(6)	chancroid - 24 hours;
12	(7)	chikungunya virus infection - 24 hours;
13	(8)	chlamydial infection (laboratory confirmed) - 7 days;
14	(9)	cholera - 24 hours;
15	(10)	Creutzfeldt-Jakob disease – 7 days;
16	(11)	cryptosporidiosis – 24 hours;
17	(12)	cyclosporiasis – 24 hours;
18	(13)	dengue - 7 days;
19	(14)	diphtheria - 24 hours;
20	(15)	Escherichia coli, shiga toxin-producing - 24 hours;
21	(16)	ehrlichiosis – 7 days;
22	(17)	encephalitis, arboviral - 7 days;
23	(18)	foodborne disease, including Clostridium perfringens, staphylococcal, Bacillus cereus, and other
24		and unknown causes - 24 hours;
25	(19)	gonorrhea - 24 hours;
26	(20)	granuloma inguinale - 24 hours;
27	(21)	Haemophilus influenzae, invasive disease - 24 hours;
28	(22)	Hantavirus infection – 7 days;
29	(23)	Hemolytic-uremic syndrome – 24 hours;
30	(24)	Hemorrhagic fever virus infection – immediately;
31	(25)	hepatitis A - 24 hours;
32	(26)	hepatitis B - 24 hours;
33	(27)	hepatitis B carriage - 7 days;
34	(28)	hepatitis C, acute – 7 days;
35	(29)	human immunodeficiency virus (HIV) infection confirmed - 24 hours;
36	(30)	influenza virus infection causing death – 24 hours;
37	(31)	legionellosis - 7 days;

1	(32)	leprosy – 7 days;
2	(33)	leptospirosis - 7 days;
3	(34)	listeriosis – 24 hours;
4	(35)	Lyme disease - 7 days;
5	(36)	lymphogranuloma venereum - 7 days;
6	(37)	malaria - 7 days;
7	(38)	measles (rubeola) - 24 hours;
8	(39)	meningitis, pneumococcal - 7 days;
9	(40)	meningococcal disease - 24 hours;
10	(41)	Middle East respiratory syndrome (MERS) - 24 hours;
11	(42)	monkeypox – 24 hours;
12	(43)	mumps - 7 days;
13	(44)	nongonococcal urethritis - 7 days;
14	(45)	novel influenza virus infection – immediately;
15	(46)	plague - immediately;
16	(47)	paralytic poliomyelitis - 24 hours;
17	(48)	pelvic inflammatory disease – 7 days;
18	(49)	psittacosis - 7 days;
19	(50)	Q fever - 7 days;
20	(51)	rabies, human - 24 hours;
21	(52)	Rocky Mountain spotted fever - 7 days;
22	(53)	rubella - 24 hours;
23	(54)	rubella congenital syndrome - 7 days;
24	(55)	salmonellosis - 24 hours;
25	(56)	severe acute respiratory syndrome (SARS) – 24 hours;
26	(57)	shigellosis - 24 hours;
27	(58)	smallpox - immediately;
28	(59)	Staphylococcus aureus with reduced susceptibility to vancomycin – 24 hours;
29	(60)	streptococcal infection, Group A, invasive disease - 7 days;
30	(61)	syphilis - 24 hours;
31	(62)	tetanus - 7 days;
32	(63)	toxic shock syndrome - 7 days;
33	(64)	trichinosis - 7 days;
34	(65)	tuberculosis - 24 hours;
35	(66)	tularemia – immediately;
36	(67)	typhoid - 24 hours;
37	(68)	typhoid carriage (Salmonella typhi) - 7 days;

1	(69) typhus	, epidemic (louse-borne) - 7 days;			
2	(70) vaccin	vaccinia – 24 hours;			
3	(71) vibrio	vibrio infection (other than cholera) – 24 hours;			
4	(72) whooping cough -24 hours; and				
5	(73) yellow	fever - 7 days: days; and			
6	<u>(74) Zika v</u>	irus infection – 24 hours.			
7	(b) For purposes of repo	orting, "confirmed human immunodeficiency virus (HIV) infection" is defined as a positive			
8	virus culture, repeatedly reactive EIA antibody test confirmed by western blot or indirect immunofluorescent				
9	antibody test, positive nucleic acid detection (NAT) test, or other confirmed testing method approved by the				
10	Director of the State Public Health Laboratory conducted on or after February 1, 1990. In selecting additional tests				
11	for approval, the Direc	tor of the State Public Health Laboratory shall consider whether such tests have been			
12	approved by the federal	Food and Drug Administration, recommended by the federal Centers for Disease Control			
13	and Prevention, and endorsed by the Association of Public Health Laboratories.				
14	(c) In addition to the	laboratory reports for Mycobacterium tuberculosis, Neisseria gonorrhoeae, and syphilis			
15	specified in G.S. 130A-139, laboratories shall report:				
16	(1) Isolatio	on or other specific identification of the following organisms or their products from human			
17	clinica	l specimens:			
18	(A)	Any hantavirus or hemorrhagic fever virus.			
19	(B)	Arthropod-borne virus (any type).			
20	(C)	Bacillus anthracis, the cause of anthrax.			
21	(D)	Bordetella pertussis, the cause of whooping cough (pertussis).			
22	(E)	Borrelia burgdorferi, the cause of Lyme disease (confirmed tests).			
23	(F)	Brucella spp., the causes of brucellosis.			
24	(G)	Campylobacter spp., the causes of campylobacteriosis.			
25	(H)	Chlamydia trachomatis, the cause of genital chlamydial infection, conjunctivitis (adult			
26		and newborn) and pneumonia of newborns.			
27	(I)	Clostridium botulinum, a cause of botulism.			
28	(J)	Clostridium tetani, the cause of tetanus.			
29	(K)	Corynebacterium diphtheriae, the cause of diphtheria.			
30	(L)	Coxiella burnetii, the cause of Q fever.			
31	(M)	Cryptosporidium parvum, the cause of human cryptosporidiosis.			
32	(N)	Cyclospora cayetanesis, the cause of cyclosporiasis.			
33	(0)	Ehrlichia spp., the causes of ehrlichiosis.			
34	(P)	Shiga toxin-producing Escherichia coli, a cause of hemorrhagic colitis, hemolytic uremic			
35		syndrome, and thrombotic thrombocytopenic purpura.			
36	(Q)	Francisella tularensis, the cause of tularemia.			
37	(R)	Hepatitis B virus or any component thereof, such as hepatitis B surface antigen.			

1		(S)	Human	Immunodeficiency Virus, the cause of AIDS.	
2		(T)	Legion	ella spp., the causes of legionellosis.	
3		(U)	Leptos	pira spp., the causes of leptospirosis.	
4		(V)	Listeria	a monocytogenes, the cause of listeriosis.	
5		(W)	Middle	East respiratory syndrome virus.	
6		(X)	Monke	ypox.	
7		(Y)	Mycob	acterium leprae, the cause of leprosy.	
8		(Z)	Plasmo	dium falciparum, P. malariae, P. ovale, and P. vivax, the causes of malaria in	
9			human	S.	
10		(AA)	Poliovi	rus (any), the cause of poliomyelitis.	
11		(BB)	Rabies	virus.	
12		CC)	Rickett	sia rickettsii, the cause of Rocky Mountain spotted fever.	
13		(DD)	Rubella	a virus.	
14		(EE)	Salmor	ella spp., the causes of salmonellosis.	
15		(FF)	Shigell	a spp., the causes of shigellosis.	
16		(GG)	Smallp	ox virus, the cause of smallpox.	
17		(HH)	Staphy	lococcus aureus with reduced susceptibility to vanomycin.	
18		(II)	Trichin	ella spiralis, the cause of trichinosis.	
19		(JJ)	Vaccin	ia virus.	
20		(KK)	Vibrio	spp., the causes of cholera and other vibrioses.	
21		(LL)	Yellow	fever virus.	
22		(MM)	Yersini	a pestis, the cause of plague.	
23	(2)	Isolatio	Isolation or other specific identification of the following organisms from normally sterile human		
24		body si	body sites:		
25		(A)	Group	A Streptococcus pyogenes (group A streptococci).	
26		(B)	Haemo	philus influenzae, serotype b.	
27		(C)	Neisser	ria meningitidis, the cause of meningococcal disease.	
28	(3)	Positive	e serolog	ic test results, as specified, for the following infections:	
29		(A)	Fourfo	ld or greater changes or equivalent changes in serum antibody titers to:	
30			(i)	Any arthropod-borne viruses associated with meningitis or encephalitis in a	
31				human.	
32			(ii)	Any hantavirus or hemorrhagic fever virus.	
33			(iii)	Chlamydia psittaci, the cause of psittacosis.	
34			(iv)	Coxiella burnetii, the cause of Q fever.	
35			(v)	Dengue virus.	
36			(vi)	Ehrlichia spp., the causes of ehrlichiosis.	
37			(vii)	Measles (rubeola) virus.	

1		(viii)	Mumps virus.	
2		(ix)	Rickettsia rickettsii, the cause of Rocky Mountain spotted fever.	
3		(x)	Rubella virus.	
4		(xi)	Yellow fever virus.	
5	(B)	The pre	esence of IgM serum antibodies to:	
6		(i)	Chlamydia psittaci.	
7		(ii)	Hepatitis A virus.	
8		(iii)	Hepatitis B virus core antigen.	
9		(iv)	Rubella virus.	
10		(v)	Rubeola (measles) virus.	
11		(vi)	Yellow fever virus.	
12	(4) Labora	tory resul	ts from tests to determine the absolute and relative counts for the T-helper (CD4)	
13	subset	of lymph	ocytes and all results from tests to determine HIV viral load.	
14	(d) Laboratories utilizing	g electror	ic laboratory reporting (ELR) shall report all positive laboratory results from tests	
15	used to diagnosis hepatiti	s C infec	tion, including: including the following:	
16	(1) Hepatitis C virus antibody tests (including the test specific signal to cut-off (s/c)-ratio), ratio:			
17	(2) Hepatitis C nucleic acid tests, tests;			
18	(3) Hepatitis C antigen(s) tests, tests; and			
19	(4) Hepatitis C g	genotypic	tests.	
20				
21	History Note:	Author	ity G.S. 130A-134; 130A-135; 130A-139; 130A-141:	
22		Amend	ed Eff. October 1, 1994; February 1, 1990;	
23		Tempo	rary Amendment Eff. July 1, 1997;	
24		Amend	ed Eff. August 1, 1998;	
25		Tempo	rary Amendment Eff. February 13, 2003; October 1, 2002; February 18, 2002;	
26		June 1,	2001;	
27		Amend	ed Eff. April 1, 2003;	
28		Tempo	rary Amendment Eff. November 1, 2003; May 16, 2003;	
29		Amend	ed Eff. January 1, 2005; April 1, 2004;	
30		Tempo	rary Amendment Eff. June 1, 2006;	
31		Amend	ed Eff. April 1, 2008; November 1, 2007; October 1, 2006;	
32		Tempo	rary Amendment Eff. January 1, 2010;	
33		Tempo	rary Amendment Expired September 11, 2011;	
34		Amend	ed Eff. July 1, 2013;	
35		Tempo	rary Amendment Eff. December 2, 2014;	
36		Amend	ed Eff. October 1, 2015;	
37		Emerge	ency Amendment Eff. March 1, 2016;	

1	Temporary Amendment Eff. July 1, 2016. 2016;
2	<u>Amended Eff 10 1, 2016.</u>
3	